Ironwood Pharma (IRWD) Price & Analysis

Compare

321 Followers

IRWD Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.53 - $5.21

Previous CloseN/A

Volume359.32K

Average Volume (3M)1.48M

Market Cap

$206.29M

Enterprise Value$632.64M

Total Cash (Recent Filing)$108.48M

Total Debt (Recent Filing)$599.08M

Price to Earnings (P/E)85.7

Beta0.65

Next Earnings

Nov 06, 2025

EPS Estimate

0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.14

Shares Outstanding162,434,130

10 Day Avg. Volume1,594,021

30 Day Avg. Volume1,479,649

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap3.07

Enterprise Value/Revenue1.99

Enterprise Value/Gross Profit2.21

Enterprise Value/Ebitda10.50

Forecast

1Y Price Target

$1.00

Price Target Upside-21.26% Downside

Rating ConsensusHold

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Financial PerformanceLinzess revenues of $248M for 2Q25 appear on track to meet guidance of $800-850M and reflect normalization of gross-to-net accounting fluctuations.

Revenue GuidanceManagement expects the rest of the year to show similar strength as 2Q, with guidance for $260-290M total revenue and adjusted EBITDA greater than $105M reiterated.

Bears Say

Debt ChallengesThe high debt load and delay in apraglutide's revenue contribution mean there will likely be no meaningful revenue contribution until after Linzess' loss of exclusivity and debt maturity.

Regulatory SetbacksAn additional confirmatory Phase 3 trial for apraglutide in short bowel syndrome is needed for approval, adding financial uncertainty to the company.

Ironwood Pharma News

Ironwood Pharmaceuticals Reports Strong Q2 2025 Results

Ironwood Pharmaceuticals ( ($IRWD) ) has released its Q2 earnings. Here is a breakdown of the information Ironwood...

18d ago

IRWD

Ironwood Pharmaceuticals (IRWD) Q2 Earnings Cheat Sheet

Ironwood Pharmaceuticals (IRWD) is scheduled to report 2nd quarter earnings on 08/07/2025. Regarding Q2 estimates, Wall Street analysts...

21d ago

IRWD

Ironwood Pharma Elects Directors at Annual Meeting

Ironwood Pharma ( ($IRWD) ) has shared an update. On June 10, 2025, Ironwood Pharmaceuticals held its Annual...

2M ago

IRWD

Ironwood Pharma Receives Nasdaq Deficiency Letter

Ironwood Pharma ( ($IRWD) ) just unveiled an update. On May 28, 2025, Ironwood Pharmaceuticals received a deficiency...

3M ago

IRWD

Ironwood Pharmaceuticals Reports Q1 2025 Financial Results

Ironwood Pharmaceuticals ( ($IRWD) ) has released its Q1 earnings. Here is a breakdown of the information Ironwood...

4M ago

IRWD

Ironwood reports Q1 EPS (14c), two estimates (3c)

Reports Q1 revenue $41.1M, consensus $56.7M. The company states: ” The year-over-year decrease in total revenue reflects a...

4M ago

IRWD

Ironwood affirms FY25 revenue $260M-$290M, consensus $286.8M

Affirms U.S. LINZESS Net Sales view of $800M – $850M. High single digit prescription demand growth, more than...

4M ago

IRWD

Ironwood Pharma: Hold Rating Maintained Amid Revenue Uncertainty and Long-term Concerns

Mohit Bansal, an analyst from Wells Fargo, maintained the Hold rating on Ironwood Pharma (IRWD – Research Report)....

4M ago

IRWD

IRWD Earnings this Week: How Will it Perform?

Ironwood Pharmaceuticals (IRWD) is scheduled to report 1st quarter earnings on 05/01/2025. Regarding Q1 estimates, Wall Street analysts...

4M ago

IRWD

Ironwood backs FY25 revenue view $260M-$290M, consensus $287.07M

Raises FY25 adjusted EBITDA view to greater than $105M from greater than $85M. “Today, we are reiterating our...

4M ago

IRWD

Ironwood downgraded to Hold from Buy at Craig-Hallum

Craig-Hallum downgraded Ironwood (IRWD) to Hold from Buy with a price target of $1, down from $7, as...

4M ago

IRWD

Ironwood Pharma: Hold Rating Amid Uncertainty Over Apraglutide’s Phase 3 Trial and Strategic Options

Ironwood Pharma (IRWD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday....

4M ago

IRWD

Ironwood downgraded to Hold from Buy at Jefferies

Jefferies analyst Amy Li downgraded Ironwood (IRWD) to Hold from Buy with a price target of 70c, down...

4M ago

IRWD

Hold Rating on Ironwood Pharma Amid FDA Trial Requirements and Strategic Uncertainties

Jefferies analyst Amy Li downgraded the rating on Ironwood Pharma (IRWD – Research Report) to a Hold yesterday,...

4M ago

IRWD

IRWD FAQ

What was Ironwood Pharma’s price range in the past 12 months?

Ironwood Pharma lowest stock price was $0.53 and its highest was $5.21 in the past 12 months.

What is Ironwood Pharma’s market cap?

Ironwood Pharma’s market cap is $206.29M.

When is Ironwood Pharma’s upcoming earnings report date?

Ironwood Pharma’s upcoming earnings report date is Nov 06, 2025 which is in 73 days.

How were Ironwood Pharma’s earnings last quarter?

Ironwood Pharma released its earnings results on Aug 07, 2025. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.023 by $0.117.

Is Ironwood Pharma overvalued?

According to Wall Street analysts Ironwood Pharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Ironwood Pharma pay dividends?

Ironwood Pharma does not currently pay dividends.

What is Ironwood Pharma’s EPS estimate?

Ironwood Pharma’s EPS estimate is 0.11.

How many shares outstanding does Ironwood Pharma have?

Ironwood Pharma has 162,434,130 shares outstanding.

What happened to Ironwood Pharma’s price movement after its last earnings report?

Ironwood Pharma reported an EPS of $0.14 in its last earnings report, beating expectations of $0.023. Following the earnings report the stock price went up 10%.

Which hedge fund is a major shareholder of Ironwood Pharma?

Currently, no hedge funds are holding shares in IRWD

Ironwood Pharma Stock Smart Score

Underperform

Fundamentals

Return on Equity

-8.02%

Trailing 12-Months

Asset Growth

-13.31%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ironwood Pharma

Ironwood Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal (GI) diseases. Headquartered in Cambridge, Massachusetts, Ironwood specializes in creating products aimed at improving patient outcomes in conditions such as irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC). Its flagship product, linaclotide, marketed under the brand name Linzess, is a prescription medication designed to treat these GI disorders, offering relief through a novel mechanism of action.

Ironwood Pharma (IRWD) Earnings & Revenues

Historic Earnings Reports

IRWD Stock 12 Month Forecast

Average Price Target

$1.00

▼(-21.26% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","3":"$3","5":"$5","7":"$7","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.77,0.7876923076923077,0.8053846153846154,0.823076923076923,0.8407692307692308,0.8584615384615385,0.8761538461538462,0.8938461538461538,0.9115384615384615,0.9292307692307693,0.946923076923077,0.9646153846153847,0.9823076923076923,{"y":1,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.77,0.7876923076923077,0.8053846153846154,0.823076923076923,0.8407692307692308,0.8584615384615385,0.8761538461538462,0.8938461538461538,0.9115384615384615,0.9292307692307693,0.946923076923077,0.9646153846153847,0.9823076923076923,{"y":1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.77,0.7876923076923077,0.8053846153846154,0.823076923076923,0.8407692307692308,0.8584615384615385,0.8761538461538462,0.8938461538461538,0.9115384615384615,0.9292307692307693,0.946923076923077,0.9646153846153847,0.9823076923076923,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.59,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.06,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.02,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.62,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.77,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >